2018
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2018, 37: 423-438. PMID: 30452337, DOI: 10.1200/jco.18.01160.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine treatmentASCO Clinical Practice GuidelineAdjuvant endocrine therapySecond breast cancerClinical practice guidelinesBreast cancer recurrenceBreast cancerEndocrine treatmentAI treatmentEndocrine therapyExtended therapyCancer recurrencePractice guidelinesHormone receptor-positive breast cancerNode-positive breast cancerNode-negative breast cancerReceptor-positive breast cancerAdjuvant AI therapyNode-positive cancersOverall survival advantageContralateral breast cancerYears of therapyRandomized clinical trialsAromatase inhibitor treatmentAI therapy
2016
Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy
Knobf MT, Jeon S, Smith B, Harris L, Kerstetter J, Thompson AS, Insogna K. Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy. Breast Cancer Research And Treatment 2016, 155: 491-500. PMID: 26850265, DOI: 10.1007/s10549-016-3693-3.Peer-Reviewed Original ResearchConceptsFemale cancer survivorsPhysical activity groupEndocrine therapyBone outcomesExercise interventionBone lossFemoral neckAromatase inhibitorsActivity groupAdjuvant AI therapyChemotherapy-induced menopauseSufficient serum levelsAdjuvant endocrine therapyVitamin D supplementsHealthy postmenopausal womenLess bone lossHome-based groupSignificant BMD lossSignificant clinical problemMajority of subjectsAI therapyD supplementsPostmenopausal womenBMD lossBMD outcomes
2011
OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.
Adelson K, Raptis G, Sparano J, Germain D. OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457. Cancer Research 2011, 71: ot3-01-01-ot3-01-01. DOI: 10.1158/0008-5472.sabcs11-ot3-01-01.Peer-Reviewed Original ResearchMedian progression-free survivalMetastatic breast cancerProgression-free survivalAI therapyPostmenopausal womenMetastatic diseaseAI-resistant metastatic breast cancerResistant metastatic breast cancerAdjuvant AI therapyAI-resistant diseaseClinical benefit ratePrior chemotherapy regimenPhase II studyAdverse event ratesAddition of bortezomibHuman breast cancer cell linesEstrogen-receptor positiveRandomized phase II designsBreast cancer cell linesPhase II designUnfolded protein responseChemotherapy regimenEligible patientsMeasurable diseasePrior chemotherapy
2008
Carpal Tunnel Syndrome Associated with the Use of Aromatase Inhibitors in Breast Cancer
Nishihori T, Choi J, DiGiovanna MP, Thomson JG, Kohler PC, McGurn J, Chung GG. Carpal Tunnel Syndrome Associated with the Use of Aromatase Inhibitors in Breast Cancer. Clinical Breast Cancer 2008, 8: 362-365. PMID: 18757265, DOI: 10.3816/cbc.2008.n.043.Peer-Reviewed Original ResearchConceptsCarpal tunnel syndromeAromatase inhibitorsBreast cancerHormone receptor-positive breast cancerCarpal Tunnel Syndrome AssociatedCommon nerve entrapment disorderReceptor-positive breast cancerOccurrence of CTSAdjuvant AI therapyJoint-related symptomsNerve entrapment syndromePotential pathophysiologic roleAdjuvant settingAI therapyHormonal therapyEntrapment syndromePostmenopausal womenPeripheral conversionSyndrome AssociatedMedian nerveTunnel syndromeRisk factorsHormonal manipulationPathophysiologic roleClinical significance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply